RNS Number : 2250H
N4 Pharma PLC
22 November 2022

22 November 2022

N4 Pharma plc

("N4 Pharma" or the "Company")

Result of Broker Offer

Total Voting Rights

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that, further to the announcement made on 18 November 2022, the Broker Offer, a facility to allow existing shareholders and other interested parties to participate on the same terms to the Placing announced on 18 November 2022, has now closed having raised a gross amount of £54,000, resulting in the issue by the Company of an additional 2,700,000 new ordinary shares of 0.4 pence each ("Broker Offer Shares").

Broker Warrants

As part of its fee, TPI will be issued with warrants ("Broker Warrants") to subscribe for 3,162,000 new ordinary shares exercisable at the Issue Price of 2 pence each, equivalent to 6 (six) per cent. of the gross aggregate value of funds raised in the Placing and Broker Offer. The Broker Warrants have a term of 36 months from the date of admission of the Broker Offer Shares to trading on AIM and are being issued under the Company's existing share authorities.

Application for Admission

Application has been made for the Broker Offer Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place at 8.00 a.m. on or around 25 November 2022. The Broker Offer Shares will rank *pari passu* with the Company's existing ordinary shares.

Total Voting Rights

Following Admission of the Broker Offer Shares, the enlarged issued share capital of the Company will comprise 233,780,349 ordinary shares of 0.4 pence each. The Company does not hold any ordinary shares in treasury. Consequently, 233,780,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Terms and definitions in this notification are as defined in the notification of 18 November 2022.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

Enquiries:

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Via IFC Advisory

SP Angel Corporate Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44(0)20 3657 0050

IFC Advisory Ltd
Financial PR
Graham Herring
Zach Cohen
Tel: +44(0)20 3934 6630

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEAEFAALPAFFA